Methylpiperazine

Methylpiperazine

SCHEMBL6424765

CN1CCNCC1.Cc1cc(C)c(C=C2C(=O)N(CN3CCN(C)CC3)c3ccccc32)[nH]1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.55
ALDH1A1 P00352 3/20 0.52
ALDH3A1 P30838 3/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
RET P07949 5/20 0.43
FGFR1 P11362 3/20 0.43
PDGFRB P09619 3/20 0.43
CSF1R P07333 2/20 0.43
SRC P12931 2/20 0.43
FLT1 P17948 2/20 0.43
FGFR3 P22607 2/20 0.43
MAPK1 P28482 2/20 0.43
FLT4 P35916 2/20 0.43
FLT3 P36888 2/20 0.43
ALK Q9UM73 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
GMNN O75496 1/20 0.43
USP2 O75604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylpiperazine SCHEMBL6424762 1.00 KDR (0.55) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL4575601 0.95 KDR (0.60) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL4575597 0.95 KDR (0.60) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL4575494 0.87 KDR (0.63) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL4575487 0.87 KDR (0.63) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL5472939 0.86 KDR (0.61) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL5472944 0.86 KDR (0.61) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL5750362 0.79 KDR (0.58) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL5750356 0.79 KDR (0.58) KDRALDH1A1ALDH3A1CA1CA2
SCHEMBL5820102 0.78 ALDH3A1 (0.58) ALDH1A1ALDH3A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1427326-A4 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN INC (US) 2005-06-08 EP disclosed
EP-1427326-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER Sugen, Inc. (US) 2004-06-16 EP disclosed
WO-2003015608-A2 COMBINATION THERAPY FOR THE TREATMENT OF CANCER SUGEN, INC. (US) 2003-02-27 WO disclosed